This Month
Health start-up Eucalyptus to ditch Woolworths, cash in on Wegovy online
The $560 million company will sack staff and stop selling products at Woolworths and Priceline and concentrate on selling weight-loss drugs online in Europe and Asia.
The stage of life Australians can’t afford to ignore
Kate Carnell says federal funds for end-of-life planning would reduce costly hospitalisations and prevent unnecessary suffering.
April
This $1.3b biotech is still run out of a spare bedroom in Melbourne
It’s been a volatile few years for Neuren, the neurological disorder treatment group which has seen shares rocket, then slump. Now it has a promising new drug.
StrongRoom AI nears sale with debts transferred to entrepreneur
The pharmacy software start-up called in administrators after its biggest investor, venture capital firm EVP, alleged it had misrepresented its finances.
In Trump’s new order, Australia must fight for affordable medicines
We must protect the principle that sovereignty, stability and fairness are not up for negotiation – even in a more transactional world.
Eli Lilly issues warning for Australia as Trump signals pharma tariffs
In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.
Drug tariffs coming; Taco Bell on block; No market bottom yet
Read everything that’s happened in the news so far today.
Trump says drug tariffs are coming ‘in not too distant future’
The president again argued too many medicines are made offshore so he was preparing a new tax on pharmaceutical imports, in a move that could hit Australia.
Pharmaceuticals to be hit by ‘major’ Trump tariff, CSL slumps 5pc
Investors are in panic as Australian drug companies could be the next victims in an expansion of the US trade war.
ASX wipes $32b; Tariffs to hit pharma; $1.3trn trade unwinds
Read everything that’s happened in the news so far today.
March
StrongRoom AI goes into administration two weeks after $70m valuation
The future of the software start-up, which will be put up for sale, has been in doubt since EVP, a venture capital investor, raised doubts about its finances.
Doctors told him he was going to die. Then AI saved his life
In labs around the world, scientists are using AI to search among existing medicines for treatments that work for rare diseases.
Trump could target our healthcare system next. We don’t need to panic
If there are retaliatory tariffs because of standing up for our PBS jewel, so be it. That would be unfortunate and unfair, but Australia can weather it.
Billions in beef exports at stake from Trump’s tariff war
US cattle ranchers and sheep graziers have recently restated their long-standing complaints against the Australian industry.
Uni side hustle grows to nearly $70m valuation
Three friends have turned their university side hustle into a software business after landing new venture capital investors.
February
Big pharma sues GenesisCare over Labor-endorsed copycat cancer drug
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund and regulate nuclear medicines escalates.
US pharma giant Cosette makes $672m bid for Mayne Pharma
US pharma giant Cosette has offered $7.40 a share for Mayne Pharmaceuticals, a premium to recent trading but a fraction of the $42 it was trading at in 2016.
January
New Chemist Warehouse riches revealed: 53 investors worth over $50m
Exclusive analysis of the share registry has unveiled for the first time just how many millionaires its merger with Sigma will mint.
Drugs from nature help millions. But there’s a catch
Big pharma and others that have made a buck from genetic resources have been asked to funnel some profit back to communities where the organisms come from.
Global pharma giants push for weight-loss drugs to be added to PBS
Eli Lilly will seek to have Mounjaro listed on the scheme this year. If successful, it would mean taxpayer subsidies for the popular obesity treatment.